Secondary Logo

ZNF582 methylation as a potential biomarker to predict cervical intraepithelial neoplasia type III/worse

A meta-analysis of related studies in Chinese population

Li, Na, MDa; He, Ya, MSb; Mi, Peng, MSc; Hu, Yuanjing, MD, PhDa,*

Section Editor(s): Wang., Jianbing

doi: 10.1097/MD.0000000000014297
Research Article: Systematic Review and Meta-Analysis

Objective: DNA methylation markers have been assessed as potential biomarkers for early cervical cancer detection. Herein, we evaluated the diagnostic performance of zinc finger protein 582 (ZNF582) methylation for cervical cancer detection.

Methods: Eligible studies were systematically searched from the electronic databases. The quality of enrolled studies was evaluated using the second version of the check list for Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). The bivariate meta-analysis model was employed to plot the summary receiver operator characteristic (SROC) curve using Stata 14.0 software. Cochran's Q test and I2 statistics were applied to assess heterogeneity among studies. Publication bias was evaluated by the Deeks’ funnel plot asymmetry test.

Results: Seven studies composed of 1749 patients were eventually included. The pooled sensitivity of ZNF582 methylation was estimated to be 0.71 [95% confidence interval (CI): 0.67–0.75] in differentiating patients with cervical intraepithelial neoplasia type III/worse (CIN3+), corresponding to a specificity of 0.81 (95% CI: 0.79–0.83) and area under the curve (AUC) of 0.85. Our stratified analysis suggested that sequential combined of HPV DNA and ZNF582 methylation test (AUC, sensitivity, and specificity of 0.876, 0.75, and 0.87, respectively) achieved higher diagnostic accuracy than single HPV DNA testing test (AUC, sensitivity and specificity of 0.669, 0.96, and 0.41, respectively).

Conclusions: ZNF582 methylation has a prospect to be an auxiliary biomarker for cervical cancer screening. A new strategy of co-testing HPV DNA and ZNF582 methylation test in cervical scrapings confers an improved diagnostic accuracy than single HPV DNA testing.

aDepartment of Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Nankai University Affiliated Hospital

bGraduate School

cDepartment of Epidemiology, Tianjin Medical University, Tianjin, China.

Correspondence: Yuanjing Hu, Department of Gynecologic Oncology, Tianjin Central Hospital of Gynecology Obstetrics, Nankai University Affiliated Hospital, No.156 Nankai San Ma Road, Nankai District, Tianjin, China (e-mail:

Abbreviations: AUC = area under the curve, CIN = cervical intraepithelial neoplasia, DOR = diagnostic odds ratio, hrHPV = high-risk human papillomavirus, NLR = negative likelihood ratio, PLR = positive likelihood ratio, SROC = summary receiver operator characteristic.

This work was supported by Science and Technology Support Project of Tianjin City (17ZXMFSY00160).

The authors have no conflicts of interest to declare.

Supplemental Digital Content is available for this article.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Received April 26, 2018

Received in revised form December 3, 2018

Accepted January 8, 2019

Back to Top | Article Outline

1 Introduction

Cervical cancer is one of the main causes of death of women worldwide.[1–3] The most widely used screening methods for cervical cancer are the cytology-based Pap smear and high-risk human papillomavirus (hrHPV) test. However, cytomorphological examination of cervical smears is not ideal because of its relatively low sensitivity.[4] Although hrHPV testing improves the sensitivity of cervical screening,[5] the specificity of hrHPV testing, especially in a young screening population, is relatively low.[6] Therefore in hrHPV primary screening programs, the less specific screening test may lead to substantially heavy burden on health care resources, such as unnecessary referral to colposcopy makes triage testing compulsory. In this respect, discovering and developing new biomarkers which confer high sensitivity and specificity for cervical cancer detection is a matter of great urgency in the clinic.

Gene silencing by promoter hypermethylation has been shown to contribute to cervical carcinogenesis and methylation analysis of cervical-cancer-specific genes has been suggested as a valuable, alternative or additive triage tool.[7–10] Among these altered and methylated genes, the ZNF582 was highlighted.[11–16] As reported, ZNF582 is frequently silenced by methylation in cervical cancers, and literature have documented the promise of ZNF582 methylation in the detection of cervical precancerous lesions.[17] In order to make a comparison of the accuracy of DNA methylation and HPV DNA testing, we performed a comprehensive meta-analysis and evaluated the diagnostic performance of ZNF582 methylation for the detection of cervical intraepithelial neoplasia (CIN) type III/worse.

Back to Top | Article Outline

2 Methods

2.1 Search strategy

This meta-analysis was conducted in compliance with the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) Statement issued in 2015.[18] Three electronic databases, Pubmed/Medline, Embase, and Cochrane, were searched for relevant studies until March 1, 2018, using the following Keywords: (cervical cancer or cervical intraepithelial neoplasia or CIN or uterine cervical neoplasm or uterine cervical dysplasia) and (methylation marker or methylation or DNA methylation) and (zinc finger protein 582 OR ZNF582 or HPV or human papillomavirus) and (screening or detection or diagnostic or diagnos*).

Back to Top | Article Outline

2.2 Study selection

The references of all publications were hand-searched in order to identify missing relevant publications. The following criteria were used for the literature selection in this meta-analysis:

  1. studies evaluated the diagnostic performance of ZNF582 methylation or HPV DNA testing in the diagnosis of high-grade squamous intraepithelial lesion (HSIL) or cervical neoplasms;
  2. studies explicitly mentioned the sample size, sensitivity, specificity and their 95% confidence intervals (CIs) or other more detailed information;
  3. Matched controls were included.

Literature was excluded according to the following criteria:

  1. the control group and sample sizes were unclear;
  2. studies without complete data including missing information of sensitivity, specificity or area under the curve (AUC) value, and so on;
  3. studies did not use histology as gold standard and
  4. basic research, animal studies, meta-analysis, review articles, letters, commentaries, abstracts presented at conferences, and so on.
Back to Top | Article Outline

2.3 Data extraction and quality assessment

All the included studies were carefully reviewed independently by 2 investigators (Li and He). All analyses were based on previously published studies, thus no ethical approval and patient consent are required. Data from these articles were extracted according to a predefined registration form. The following information was extracted: the first author, country, year of publication, patient size, study design, CIN degrees, test method, and the diagnostic results, methylation methods, cut-off value, HPV status. In studies contained both a training and a validation group, data from each group was treated as a single study in the meta-analysis. The quality of each included study was evaluated using the second version of the check list for Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) 19. A score was given to 4 domains (participant selection, triage test, reference standard, and flow & timing), based on a set of signaling questions assigned to each domain. Any disagreement was resolved by group consensus.

Back to Top | Article Outline

2.4 Statistical analysis

Statistical analysis was undertaken using Stata 14.0 (Stata Corporation, College Station, TX), and Meta-disc 1.4 (XI Cochrane Colloquium, Barcelona, Spain) software. The bivariate meta-analysis model was employed to summarize the sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR) and negative likelihood ratio (NLR) and to generate the bivariate summary receiver operator characteristic (SROC) curves with their corresponding 95% CI. The pooled diagnostic indices were calculated by using a random-effects model.[20] Heterogeneity from threshold and non-threshold effects were reflected by the Spearman correlation coefficient, Cochran's Q and I2 tests,[21] respectively. Meta-regression and subgroup analysis were performed to trace potential sources of study heterogeneity. The covariates included the following: age (average age ≤45 or >45), publication year (≤2014 or >2014), sample size (≤200 or >200), study location (China or Chinese Taipei). Deeks’ funnel plot asymmetry test was conducted to evaluate the potential publication bias, and significant level was set at P <.05.

Back to Top | Article Outline

3 Results

3.1 Study characteristics and quality

A total of 422 studies were retrieved from a primary literature search in electronic databases, and 406 studies were excluded due to the status that unrelated to ZNF582 methylation or cervical cancer diagnosis. Nine studies were left for full-text evaluation. In 1 study, the clinical accuracy calculated only in cervical adenocarcinoma was further excluded.[22] Another study didn’t use histology as gold standard was discarded as well.[23] Seven studies for ZNF582 methylation and 4 studies for HPV DNA test were included in this meta-analysis. The selection process for relevant studies is shown in Figure 1.

Figure 1

Figure 1

All of the 7 studies were conducted in Asia, including 4 studies in Chinese Taiwan and 3 in China mainland. The final diagnoses of all studies were determined by tissue-proven histopathology, and the evaluation method for DNA methylation was quantitative methylation-specific polymerase chain reaction (QMSP). The main features of each included study were described in Table 1. We evaluated the study quality of each included publications according to the QUADAS2 assessment tool.[19] As shown in Figure 2, all of the 7 studies revealed lower risks of bias, suggesting a relatively high quality of the included studies.

Table 1

Table 1

Figure 2

Figure 2

Back to Top | Article Outline

3.2 Heterogeneity

Heterogeneity from threshold and non-threshold effects was assessed using Meta-disc 1.4 software. The P-values of spearman correlation coefficient in ZNF582 methylation test, HPV DNA test, and ZNF582/HPV DNA test were more than 0.05, indicating that there was no heterogeneity from threshold effect. For the individual ZNF582 methylation test, the Cochran's-Q test yielded a Q value of 7.97 (P >.01), with I2 < 50%, suggesting that non-threshold effect is not likely to be a source of heterogeneity. However, heterogeneity generated by non-threshold effects appeared in the other pooled analyzed with P values of Cochran's Q test less than .01, accompanied by I2 >50% (Supplement Digital Content 1, which demonstrates the threshold effect analysis,

Back to Top | Article Outline

3.3 Diagnostic performance

As indicated in Table 2, the pooled accuracies for ZNF582 methylation was determined to assess their usefulness as a biomarker for screening of patients with CIN3+. The pooled sensitivity, specificity, DOR, and AUC for ZNF582 methylation test were 0.71 (95% CI: 0.67–0.75), 0.81 (95% CI: 0.79–0.83), 12.72 (95% CI: 9.93–12.68), and 0.85, respectively. The forest plots of pooled sensitivity, specificity, and SROC curves for ZNF582 methylation are displayed in Figures 3 and Supplement Digital Content 2, For the HPV DNA testing, it yielded an AUC value of 0.669, with pooled sensitivity of 0.96 (95% CI: 0.93–0.98) and specificity of 0.41 (95% CI: 0.37–0.45).

Table 2

Table 2

Figure 3

Figure 3

A random effect model was applied in the stratified meta-analyses due to the existence of significant heterogeneities among studies. We further validated the diagnostic accuracy of the parallel and sequential combinations of ZNF582/HPV DNA test. The results for the stratified analyses were listed in Table 2. The paralleled and sequential combinations of ZNF582/HPV tests achieved AUC values of 0.793 and 0.876, under which, the pooled sensitivity were 0.97 (95% CI: 0.94–0.99) and 0.75 (95% CI: 0.69–0.80), the pooled specificity were 0.48 (95% CI: 0.44–0.52) and 0.87 (95% CI: 0.84–0.89) respectively.

Back to Top | Article Outline

3.4 Influence assay and meta-regression

We performed influence analysis based on the platform of Stata 14.0 software. No outlier studies were identified in ZNF582 methylation test (Supplement Digital Content 3, Furthermore, meta-regression and subgroup analyses were conducted by assessing the impacts of 4 pre-specified covariates (average age, publication year, sample size, study location) on pooled sensitivity and specificity. Our data revealed that these covariates introduce heterogeneity in specificity with a P value less than .05. However, these covariates showed a low likelihood of sources of inter-study heterogeneity in sensitivity (Table 3, Supplement Digital Content 4,

Table 3

Table 3

Back to Top | Article Outline

3.5 Publication bias

The funnel plots for publication bias showed no asymmetry for the pooled ZNF582 methylation analysis. The slope of coefficient was associated with a P value of .36, implying that no publication bias existed in the studies (Supplement Digital Content 5A, For single HPV DNA test (Supplement Digital Content 5B, and paneled ZNF582 tests (data not shown) also showed a low likelihood of publication bias.

Back to Top | Article Outline

4 Discussion

Because CIN is a dynamic process, the approximate regression rates for CIN I, CIN II, and CIN III are 60%, 40%, and 33%, respectively, and their corresponding rates of progression to invasive cervical cancer are 1%, 5%, and 12%, respectively.[24] Therefore, early diagnosis and treatment of CIN can reduce cancer mortality rate through effective screening programs drastically.

Papanicolaou cytology screening programs detect most CIN with a potential to transform into malignancy and for which treatment may prevent the cancer. Unfortunately, the cytology test is difficult to implement and retain at high quality, especially in underdeveloped countries.[25] The sensitivity of HPV DNA testing is satisfactory, whereas the high prevalence of transient HPV infections had limited the specificity of this approach.[26,27] Of greater importance are accurate molecular prognostic classifiers which could be done on the screening specimen and would reflexively indicate the future risk of progression. The ability to accurately tell whether the HPV infection will become a CIN3 or disappear would radically trans-form screening programs. The results would be reduced testing, lower costs, fewer overtreatments, and less anxiety.[28]

ZNF582, located at chromosome 19q13.43, encodes the Kru[Combining Diaeresis]ppel-type zinc finger protein 582 (HGNC: 26421), which contains 1 KRAB-A-B domain and 9 zinc-finger motifs.[29] However, the biological function of ZNF582 is not yet well characterized. Most KRAB-ZNF proteins contain the KRAB (AB) domain and bind KRAB-associated protein 1 (KAP1) to co-repress gene transcription.[30,31] Members of the KRAB-ZNF family are probably involved in a variety of biological processes related to the DNA damage response, proliferation, cell cycle control, and neoplastic transformation.[30] Recent studies revealed that methylation of its promotor CPG island is an important regulating manner in epigenetics, which is closed related to the development of malignant tumor, such as oral cancer,[32,33] esophageal squamous cell carcinoma,[34] colorectal cancer,[35] and leukemia.[36]

In the development of cervical cancer, ZNF582 is silenced by hypermethylation, hence the methylation of ZNF582 has been proposed as a potential biomarker for the detection of cervical cancer.[23] As the potential diagnostic value of DNA methylation for cervical cancer screening has not yet been well elucidated thus far, we performed a comprehensive meta-analysis and evaluated the diagnostic performance of ZNF582 methylation for the detection CIN3+. And we also evaluated the pooled diagnostic accuracy of HPV DNA test from the published studies. As shown in our data, the pooled sensitivity and specificity of ZNF582 methylation was 0.71 and 0.81, respectively. Although the pooled sensitivity appeared not very high, the ROC AUC was 0.85, suggesting an overall high accuracy of this diagnostic test. DOR is one of the key indicators in assessing the accuracy of 1 diagnostic test, and that a DOR smaller than 1.0 often suggests a low discriminating value for a diagnostic test.[37,38] Importantly, the pooled DOR for ZNF582 methylation was 12.72, indicating a better discriminatory test performance of ZNF582 methylation for CIN3+ detection. Moreover, the pooled PLR of 4.19, also suggested that patients with CIN3+ had nearly 4 fold higher chance of being ZNF582 methylation test positive than individuals without CIN3+. A pooled NLR of 0.34 means that that the probability of the individuals having CIN3+ is 34% when the ZNF582 test is negative. HPV DNA test harbored much high pooled sensitivity for the detection of CIN3+, but with much lower specificity with AUC of 0.669. Our data provide evidence that ZNF582 methylation confers better diagnostic accuracy in detecting CIN3+.

We further conducted the stratified analyses to compare the diagnostic accuracy of ZNF582 methylation and HPV DNA test. Combined sequential testing of HPV DNA and ZNF582 methylation achieved an improved diagnostic accuracy compared to HPV DNA test alone with AUC and DOR of 0.876 and 19.23.

In this study, heterogeneity from non-threshold effects existed in the pooled studies. It is speculated that sample size, age, and study location may contribute to the heterogeneity sources. We further conducted influence and meta-regression analyses and our results revealed that the study location and sample size were likely to be a source of heterogeneity.

Although we did our best to conduct a comprehensive analysis, some limitations still exist. Only 7 studies were included in this meta-analysis, and all the studies included in this meta-analysis were conducted in Chinese Taipei and China. The results of this analysis in Chinese populations should be applicable to other developing countries with high incidence of CIN.

In conclusion, our meta-analysis revealed that ZNF582 achieves a promising diagnostic performance for CIN3+. And combined sequential HPV DNA and ZNF582 methylation test achieves an improved diagnostic accuracy compared to HPV DNA test alone. Therefore, we suggest that ZNF582 methylation assay can be used as an auxiliary biomarker for cervical cancer screening. Further high-quality studies from other geographies are still warranted to confirm our analyses.

Back to Top | Article Outline

Author contributions

Data curation: Na Li, Ya He.

Formal analysis: Na Li, Peng Mi.

Supervision: Yuanjing Hu.

Writing – original draft: Na Li.

Writing – review & editing: Yuanjing Hu.

Back to Top | Article Outline


[1]. Krieger N, Bassett MT, Gomez SL. Breast and cervical cancer in 187 countries between 1980 and 2010. Lancet 2011;378:1461–84.
[2]. Köse FM, Naki MM. Cervical premalignant lesions and their management. J Turkish-German Gynecol Assoc 2013;15:109–21.
[3]. Li J, Huang R, Schmidt JE, et al. Epidemiological features of Human Papillomavirus (HPV) infection among women living in Mainland China. Asian Pacific J Cancer Prev APJCP 2013;14:4015–23.
[4]. M. Arbyn AA, Jordan J, Ronco G, et al. European guidelines for quality assurance in cervical cancer screening. second edition—summary document. Eur J Cancer 2010;21:448–58.
[5]. Bulkmans N, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764–72.
[6]. Kulasingam SL, Hughes JP, Kiviat NB, et al. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral. JAMA 2002;288:1749–57.
[7]. Overmeer RM, Henken FE, Bierkens M, et al. Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 2009;219:327–36.
[8]. Saavedra KP, Brebi PM, Roa JCS. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix. Clin Epigenetics 2012;4:13–20.
[9]. Steenbergen RD, Kramer D, Braakhuis BJ, et al. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. J Natl Cancer Inst 2004;96:294–305.
[10]. Wilting SM, van Boerdonk RA, Henken FE, et al. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol Cancer 2010;9:167–81.
[11]. Liou YL, Zhang TL, Tian Y, et al. Combined clinical and genetic testing algorithm for cervical cancer diagnosis. Clin Epigenetics 2016;8:66–77.
[12]. Chang CC, Ou YC, Wang KL, et al. Triage of atypical glandular cell by SOX1 and POU4F3 methylation: a Taiwanese Gynecologic Oncology Group (TGOG) study. PLoS One 2015;10:e0128705-17.
[13]. Chang CC, Huang RL, Liao YP, et al. Concordance analysis of methylation biomarkers detection in self-collected and physician-collected samples in cervical neoplasm. BMC Cancer 2015;15:418–27.
[14]. Lin H, Chen TC, Chang TC, et al. Methylated ZNF582 gene as a marker for triage of women with Pap smear reporting low-grade squamous intraepithelial lesions—a Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol Oncol 2014;135:64–8.
[15]. Huang RL, Chang CC, Su PH, et al. Methylomic analysis identifies frequent DNA methylation of zinc finger protein 582 (ZNF582)in cervical neoplasms. PLoS One 2012;7:e41060-9.
[16]. Liou YL, Zhang Y, Liu Y, et al. Comparison of HPV genotyping and methylated ZNF582 as triage for women with equivocal liquid-based cytology results. Clin Epigenetics 2015;7:50–9.
[17]. Tian Y, Wu NYY, Liou YL, et al. Utility of gene methylation analysis, cytological examination, and HPV-16/18 genotyping in triage of high-risk human papilloma virus-positive women. Oncotarget 2011;8:62274–85.
[18]. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration & explanation. System Rev 2015;349:g7647.
[19]. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529–36.
[20]. Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a review of the concepts and methods. Arch Pathol Lab Med 1998;122:675–86.
[21]. Zamora J, Abraira V, Muriel A, et al. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol 2006;6:31.
[22]. Chang CC, Huang RL, Wang HC, et al. High methylation rate of LMX1A, NKX6-1, PAX1, PTPRR, SOX1, and ZNF582 genes in cervical adenocarcinoma. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc 2014;24:201–10.
[23]. Shen-Gunther J, Wang CM, Poage GM, et al. Molecular Pap smear: HPV genotype and DNA methylation of ADCY8, CDH8, and ZNF582 as an integrated biomarker for high-grade cervical cytology. Clin Epigenetics 2016;8:96–112.
[24]. Mccredie MR, Sharples KJ, Paul C, et al. Natural history of cervical neoplasia and risk of invasive cancer in women with cervical intraepithelial neoplasia 3: a retrospective cohort study. Lancet Oncol 2008;9:425–34.
[25]. Lazcanoponce E, Lorincz AT, Cruzvaldez A, et al. Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet 2011;378:1868–73.
[26]. Dehn D, Torkko KC, Shroyer KR. Human papillomavirus testing and molecular markers of cervical dysplasia and carcinoma. Cancer 2007;111:1–4.
[27]. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 2007;7:11–22.
[28]. Lorincz AT. Virtues and weaknesses of DNA methylation as a test for cervical cancer prevention. Acta Cytologica 2016;60:501–12.
[29]. Huntley S, Baggott DM, Hamilton AT, et al. A comprehensive catalog of human KRAB-associated zinc finger genes: insights into the evolutionary history of a large family of transcriptional repressors. Genome Res 2006;16:669–77.
[30]. Urrutia R. KRAB-containing zinc-finger repressor proteins. Genome Biol 2003;4:231–9.
[31]. Peng H, Gibson L, Ad, et al. The structurally disordered KRAB repression domain is incorporated into a protease resistant core upon binding to KAP-1-RBCC domain. J Mol Biol 2007;370:269–89.
[32]. Cheng SJ, Chang CF, Ko HH, et al. Hypermethylated ZNF582 and PAX1 genes in mouth rinse samples as biomarkers for oral dysplasia and oral cancer detection. Head Neck 2018;40:355–68.
[33]. Cheng SJ, Chang CF, Lee JJ, et al. Hypermethylated ZNF582 and PAX1 are effective biomarkers for detection of oral dysplasia and oral cancer. Oral Oncol 2016;62:34–43.
[34]. Huang J, Wang G, Tang J, et al. DNA methylation status of PAX1 and ZNF582 in esophageal squamous cell carcinoma. Int J Environ Res Public Health 2017;14:216–28.
[35]. Kumegawa K, Maruyama R, Yamamoto E, et al. A genomic screen for long noncoding RNA genes epigenetically silenced by aberrant DNA methylation in colorectal cancer. Sci Rep 2016;6:26699–712.
[36]. Figueroa ME, Lugthart S, Li Y, et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010;17:13–27.
[37]. Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003;56:1129–35.
[38]. Shen Y, Wang T, Yang T, et al. Diagnostic value of circulating microRNAs for lung cancer: a meta-analysis. Genet Test Mol Biomarkers 2013;17:359–66.

cervical cancer; diagnosis; DNA methylation; zinc finger protein 582

Supplemental Digital Content

Back to Top | Article Outline
Copyright © 2019 The Authors. Published by Wolters Kluwer Health, Inc. All rights reserved.